Enhertu (Fam-trastuzumab deruxtecan-nxki) for Breast Cancer | MyBCTeam

Connect with others who understand.

sign up Log in
About MyBCTeam
Powered By

Enhertu is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with unresectable (cannot be surgically removed) or metastatic HER2-postive breast cancer who have received at least two other therapies. Enhertu is also referred to by its drug name, fam-trastuzumab deruxtecan-nxki.

Enhertu is used as an immune targeted therapy for breast cancer. Enhertu is a combination of drugs belonging to the classes of drugs called HER2-directed antibodies and topoisomerase inhibitor conjugates. Enhertu is believed to work by binding to cancer cells and causing cell death from within.

How do I take it?
Prescribing information states that Enhertu is given as an intravenous infusion (slow injection into your vein) by a health care professional. Enhertu is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Enhertu is available only as an intravenous infusion.

Side effects
The FDA-approved label for Enhertu lists common side effects including nausea, fatigue, vomiting, hair loss, constipation, decreased appetite, anemia (low red blood cell count), neutropenia (low white blood cell count), diarrhea, cough, and thrombocytopenia (low blood platelet count).

Rare but serious side effects listed for Enhertu include heart failure.

For more details about this treatment, visit:

Enhertu — Daiichi-Sankyo and Aztrazeneca

Enhertu — Breastcancer.org

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in